scispace - formally typeset
Open AccessJournal ArticleDOI

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

Reads0
Chats0
TLDR
In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2.
About
This article is published in Cell.The article was published on 2021-04-29 and is currently open access. It has received 1109 citations till now. The article focuses on the topics: Vaccination & Humoral immunity.

read more

Citations
More filters
Journal ArticleDOI

Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates

- 01 May 2022 - 
TL;DR: In this paper , the authors evaluated the immunogenicity of INO-4800, a synthetic DNA vaccine candidate for COVID-19 currently in clinical evaluation, and InO-4802, a next-generation DNA vaccine designed to broadly target emerging SARS-CoV-2 variants, as booster vaccines in nonhuman primates.
Journal ArticleDOI

Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination

TL;DR: In this paper , two new formulations, mRNA and adenoviral vector vaccines, which have varying efficacy rates, potentially related to their distinct capacities to induce humoral immune responses were evaluated.
Journal ArticleDOI

Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate

TL;DR: RBD-CD immunogenicity evaluated in mice and non-human primates (NHP) indicated that recombinant protein was able to induce a specific and high IgG response after two doses and could improve the current vaccines against COVID-19.
Posted ContentDOI

Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant

TL;DR: In this paper, the authors used nine epidemiological and population datasets collected in New York City (NYC), where B.1.526 emerged, and comprehensive modeling to estimate the changes in transmissibility, immune escape potential, and infection fatality risk.
References
More filters
Journal ArticleDOI

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

TL;DR: Infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein, and SARS-CoV-2-reactive T cells were found in individuals who had recovered from SARS or COVID-19 and in unexposed donors, although with different patterns of immunoreactivity.
Related Papers (5)